Abstract
Lipoprotein(a) [Lp(a)] is a lipoprotein in which apolipoproteinB-100 is linked to apolipoprotein(a) [apo(a)]. Significant variation in Lp(a) concentration is specific to LPA gene, which codes for apo(a). Nicotinic acid (NA) is used for treatment of dyslipidemias, and the lowering effect of NA on Lp(a) has been previously reported. To evaluate the Lp(a) lowering effect of 1g/20mg and 2g/40mgday of Nicotinic acid/Laropiprant in subjects with different baseline Lp(a) concentrations and depending on the LPA genotype. In an open-label, 10-week study, 1g/20mgday of NA/Laropiprant for 4weeks followed by 6weeks of 2g/40mgday conducted at 3 centers in Spain, 82 subjects were enrolled. Patients were studied at baseline and at the end of both treatment periods and were enrolled in three groups: normal Lp(a) (<50mg/dL), high Lp(a) (50-120mg/dL) and very high Lp(a) (>120mg/dL). The LPA genetic polymorphism was analyzed by a real-time PCR. There was a significant difference in LPA genotypes among Lp(a) concentration groups and an inverse and significant correlation between baseline Lp(a) concentration and LPA genotype was found (R=-0.372, p<0.001). There were a significant decrease in total cholesterol, triglycerides, LDL cholesterol, apo B ...Continue Reading
References
Jul 1, 1992·The Journal of Clinical Investigation·E BoerwinkleH H Hobbs
Nov 17, 1989·Science·G Utermann
Nov 1, 1985·Atherosclerosis·A GurakarH B Brewer
Nov 12, 1987·Nature·J W McLeanR M Lawn
Oct 11, 1994·Biochemistry·S FrankG M Kostner
Aug 11, 1994·Nature·D J GraingerJ C Metcalfe
Jun 1, 1993·Atherosclerosis·M SeedB L Knight
Jun 12, 2003·Metabolism: Clinical and Experimental·Ann M PoyntenLesley V Campbell
Mar 1, 2008·The American Journal of Cardiology·John F PaoliniChristie M Ballantyne
Jun 14, 2008·The American Journal of Cardiology·Angelo M Scanu, Ravi Bamba
Apr 3, 2008·Mayo Clinic Proceedings·Ronald B Goldberg, Terry A Jacobson
Dec 9, 2008·Journal of Lipid Research·Matthew B LanktreeRobert A Hegele
Jun 11, 2009·JAMA : the Journal of the American Medical Association·Pia R KamstrupBørge G Nordestgaard
Jul 23, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Sep 11, 2010·Journal of the American College of Cardiology·Sotirios TsimikasS Matthijs Boekholdt
Mar 23, 2011·Current Pharmaceutical Design·I Gouni-Berthold, H K Berthold
Apr 7, 2012·Atherosclerosis·María Solanas-BarcaAna Cenarro
Aug 30, 2012·Journal of Lipid Research·Indumathi ChennamsettyGerhard M Kostner
Oct 9, 2012·Metabolism: Clinical and Experimental·Jane Hoover-Plow, Menggui Huang
Nov 2, 2012·The New England Journal of Medicine·Eli M RothEvan A Stein
Jan 30, 2013·Atherosclerosis. Supplements·Heiner K Berthold, Ioanna Gouni-Berthold
Feb 28, 2013·European Heart Journal·UNKNOWN HPS2-THRIVE Collaborative Group
Jun 6, 2013·European Heart Journal·Karam M KostnerGerhard M Kostner
Sep 17, 2013·Metabolism: Clinical and Experimental·Beth A ConnollyWilliam W Bachovchin
Citations
Dec 4, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Hayato TadaKenshi Hayashi
May 14, 2016·Metabolism: Clinical and Experimental·Pei WangChao-Yu Miao
Sep 16, 2015·Canadian Journal of Physiology and Pharmacology·Ulrich Julius
Oct 14, 2016·Metabolism: Clinical and Experimental·Amirhosssein SahebkarArrigo F G Cicero
Dec 30, 2016·International Journal of Clinical Practice·Panagiotis AnagnostisDimitrios G Goulis
Dec 8, 2015·Journal of Lipid Research·Julian C van CapelleveenErik S G Stroes
Feb 2, 2019·Current Pharmaceutical Design·Michele ScognamiglioClaudio Napoli
Feb 6, 2015·Molecular Systems Biology·Yansheng LiuRuedi Aebersold
Apr 9, 2020·European Heart Journal·Lotte C A StiekemaMahnoush Bahjat
Jul 9, 2020·Journal of Clinical Medicine·Maria Francesca GrecoMassimiliano Ruscica